SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-16-113534
Filing Date
2016-04-22
Accepted
2016-04-22 16:20:59
Documents
5
Effectiveness Date
2016-04-22

Document Format Files

Seq Description Document Type Size
1 DEFA14A a16-2458_3defa14a.htm DEFA14A 34163
2 GRAPHIC g24583bci001.gif GRAPHIC 72642
3 GRAPHIC g24583bci002.gif GRAPHIC 111962
4 GRAPHIC g24583bci003.gif GRAPHIC 60991
5 GRAPHIC g24583bci004.gif GRAPHIC 36943
  Complete submission text file 0001104659-16-113534.txt   424661
Mailing Address 525 UNIVERSITY AVENUE SUITE 610 PALO ALTO CA 94301
Business Address 525 UNIVERSITY AVENUE SUITE 610 PALO ALTO CA 94301 6504625800
Ocera Therapeutics, Inc. (Filer) CIK: 0001274644 (see all company filings)

IRS No.: 631192270 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35119 | Film No.: 161586930
SIC: 2834 Pharmaceutical Preparations